Company intelligence / Profile preview

Suzhou Hepa Thera Biopharmaceutical

Ownership: Private
Development stage: Preclinical

Overview

Suzhou Hepa Thera Biopharmaceutical has initiated Phase I clinical trials of its lead candidate HT101, an N-acetylgalactosamine-conjugated siRNA targeting chronic hepatitis B. Early data presented at EASL Congress in June 2024 included efficacy and adverse event results from a phase Ib trial as well as pharmacodynamics data from preclinical studies. The company also collaborates on another HBV program, HT102/BM012, which has completed Phase I safety and tolerability studies.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: small interfering RNA (siRNA)RNA therapeuticsAmidesAmino sugars
Industry: Biotech

Drug pipeline

2 assets

HT-101

Pre-clinical

Indications: Hepatitis B

1 more asset in the full pipeline.

Request access →

Partnerships

Incubation/investment partnership with Fosun Pharma’s health innovation fundspossible collaboration with Biomissile on BM012/HT102 program

Beyond the preview

Go deeper on Suzhou Hepa Thera Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Hepa Thera Biopharmaceutical.

Explore the full profile